Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Submitted by
admin
on November 1, 2016 - 10:13am
Source:
Fierce Pharma
News Tags:
Eli Lilly
Jardiance
FDA
diabetes
Boehringer Ingelheim
Headline:
Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Do Not Allow Advertisers to Use My Personal information
